ERSP warns Beveragette not to overstate efficacy claims
This article was originally published in The Tan Sheet
Executive SummaryBeveragette Ventures can keep marketing claims that its GEM Keep It Cool Menopause Relief Drink reduces symptoms of menopause, but should drop modifiers like "dramatically" and "significantly," the Electronic Retailing Self-Regulation Program says in a report released Feb. 11. The industry watchdog explained the modifiers and testimonials suggesting consumers would receive "immediate results" overstated "the breadth of evidence" the firm submitted. However, the firm provided sufficient data to support claims that its supplement, made mostly of natural extract from black cohosh root, could help alleviate menopause-related hot flashes, night sweats and irritability. Beveragette said it would comply with the recommendations
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.